株探米国株
日本語 英語
エドガーで原本を確認する
METLIFE INC false 0001099219 0001099219 2023-05-25 2023-05-25 0001099219 us-gaap:CommonStockMember 2023-05-25 2023-05-25 0001099219 us-gaap:SeriesAPreferredStockMember 2023-05-25 2023-05-25 0001099219 us-gaap:SeriesEPreferredStockMember 2023-05-25 2023-05-25 0001099219 us-gaap:SeriesFPreferredStockMember 2023-05-25 2023-05-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 25, 2023

 

 

METLIFE, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

1-15787   13-4075851
(Commission
File Number)
  (IRS Employer
Identification No.)

 

200 Park Avenue, New York, NY   10166-0188
(Address of Principal Executive Offices)   (Zip Code)

(212) 578-9500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01   MET   New York Stock Exchange
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01   MET PRA   New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E   MET PRE   New York Stock Exchange
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F   MET PRF   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 7.01 Regulation FD Disclosure.

On May 25, 2023, MetLife, Inc., a Delaware corporation (the “Company”) issued a news release announcing that two of its subsidiaries, Metropolitan Life Insurance Company, a New York-domiciled insurance company (“MLIC”), and Metropolitan Tower Life Insurance Company, a Nebraska-domiciled insurance company (“MTL” and, together with MLIC, the “Ceding Companies”), entered into a Master Transaction Agreement (the “Master Agreement”) with Commonwealth Annuity and Life Insurance Company, a Massachusetts-domiciled corporation (“CwA”), and First Allmerica Financial Life Insurance Company, a Massachusetts-domiciled insurance company (“FAFLIC” and, together with CwA, the “Reinsurers”), and the transactions contemplated thereby. Additional details about this transaction can be found in such news release, which is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

In addition, the slide presentation attached as Exhibit 99.2 to this Form 8-K and incorporated herein by reference, will be presented at MetLife, Inc.’s investor conference related to this transaction on May 25, 2023.

As provided in General Instruction B.2 of Form 8-K, the information and exhibits provided pursuant to this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On May 25, 2023, MLIC and MTL entered into the Master Agreement, pursuant to which, among other things, at the closing of the transactions contemplated thereby, (i) MLIC and FAFLIC will enter into a coinsurance and modified coinsurance agreement (the “MLIC Reinsurance Agreement”) and (ii) MTL and CwA will enter into a coinsurance and modified coinsurance agreement (the “MTL Reinsurance Agreement” and, together with the MLIC Reinsurance Agreement, the “Reinsurance Agreements”), pursuant to which, upon the terms and subject to the conditions set forth therein, the applicable Ceding Company will cede to the applicable Reinsurer, and the applicable Reinsurer will reinsure, on a combined coinsurance and modified coinsurance basis, (x) solely in the case of MLIC, 25% of the reinsured liabilities (as described in the Master Agreement) with respect to certain retail universal life insurance policies with secondary guarantees described therein, the remaining portion of which are reinsured to MetLife Reinsurance Company of Vermont, and (y) in the case of both MLIC and MTL, 100% of the reinsured liabilities with respect to other retail universal life, universal life with supplemental guarantees and variable universal life insurance policies and retail fixed deferred annuities and fixed and variable immediate annuity contracts described therein (the “Reinsured Contracts”).

In connection therewith, at the closing of such transactions, MLIC and FAFLIC will enter into a trust agreement with U.S. Bank National Association (the “Trustee”) (the “MLIC Trust Agreement”) and MTL and CwA will enter into a trust agreement with the Trustee (the “MTL Trust Agreement” and, together with the MLIC Trust Agreement, the “Trust Agreements”), pursuant to which, upon the terms and subject to the conditions set forth therein, the applicable Reinsurer will establish with the Trustee a trust account for the benefit of such applicable Ceding Company to collateralize its obligations under the applicable Reinsurance Agreement (each a “Trust Account” and, together, the “Trust Accounts”), and assets supporting the general account liabilities relating to the applicable Reinsured Contracts will be deposited into the applicable Trust Account. Each Ceding Company will reinsure the separate accounts relating to the Reinsured Contracts on a modified coinsurance basis. CwA will provide a guarantee of FAFLIC’s payment obligations to MLIC and trust funding obligations under the MLIC Reinsurance Agreement. In addition, the investment of assets in the Trust Accounts will be subject to investment guidelines and certain capital adequacy related triggers will require enhanced funding. The Reinsurance Agreements will also contain additional counterparty risk management and mitigation provisions.

In consideration of MLIC and MTL entering into the applicable Reinsurance Agreement and the transactions contemplated thereby, MLIC and MTL will each receive an aggregate ceding commission of $1,770 million, in the case of MLIC, and $480 million, in the case of MTL, in each case subject to adjustments as contemplated by the Master Agreement, based primarily on changes in the equity markets between a valuation date and the closing of the transactions.

 

2


Under the terms of the Master Agreement, at the closing of the transactions, MetLife Investment Management, LLC, an affiliate of the Company (“MIM”), will enter into an investment advisory agreement with each of CwA and FAFLIC, pursuant to which MIM will be the preferred investment manager for approximately 40% of the general account assets to be transferred to the Trust Accounts upon closing, for a minimum of five years, subject to certain provisions and exceptions. MLIC and MTL or their affiliates will each continue to administer the applicable Reinsured Contracts.

The Master Agreement contains customary representations and warranties as well as covenants by each of the parties. The representations and warranties in the Master Agreement are the product of negotiation among the parties to the Master Agreement and are for the sole benefit of such parties. Any inaccuracies of such representations and warranties are subject to waiver by such parties in accordance with the Master Agreement without notice or liability to any other person. In some instances, the representations and warranties in the Master Agreement may represent an allocation among the parties of risk associated with particular matters, and the assertions embodied in those representations and warranties are qualified by information disclosed by one party to the other in connection with the execution of the Master Agreement. Consequently, persons other than the parties to the Master Agreement may not rely upon the representations and warranties in the Master Agreement as characterizations of actual facts or circumstances as of the date of the Master Agreement or as of any other date. Each of the Ceding Companies and Reinsurers has agreed to indemnify the relevant other party and its respective affiliates with respect to certain losses arising out of or resulting from breaches of its representations, warranties and covenants, as well as for certain other matters.

The transactions are expected to close in the second half of 2023. The consummation of the closing under the Master Agreement is subject to the satisfaction or waiver of customary closing conditions specified in the Master Agreement, including, among other things, (i) the receipt of required regulatory approvals, without imposing a burdensome condition, and (ii) absence of a material adverse effect on the Reinsurers (in the case of the Ceding Companies) or on the business of the Reinsured Contracts (in the case of the Reinsurers), subject to certain exceptions and qualifications.

Also on May 25, 2023, the Company announced that its Board of Directors approved an additional $1 billion authorization to repurchase its common stock.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

99.1    News Release of MetLife, Inc., dated May 25, 2023
99.2    Slide presentation to be presented at MetLife, Inc.’s investor conference on May 25, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

METLIFE, INC.
By:  

/s/ Timothy J. Ring

Name:   Timothy J. Ring
Title:   Senior Vice President and Secretary

Date: May 25, 2023

 

4

EX-99.1 2 d459413dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

For Immediate Release İ Global Communications İ MetLife, Inc.

METLIFE ANNOUNCES $19.2 BILLION RISK TRANSFER

TRANSACTION; FURTHER INCREASES SHARE REPURCHASE

AUTHORIZATION TO $4 BILLION

 

   

Agreement with Global Atlantic to reinsure approximately $19.2 billion of U.S. retail life insurance and fixed annuity statutory reserves

 

   

MetLife Board of Directors approves a further increase in share repurchase authorization to $4 billion

 

   

Transaction demonstrates MetLife’s focus on risk management and on deploying capital to its highest and best use to create long-term value for shareholders and other stakeholders

NEW YORK, May 25, 2023 – MetLife, Inc. (NYSE: MET) today announced it has entered into an agreement with Global Atlantic Financial Group (Global Atlantic), a retirement and life insurance company, to reinsure approximately $19.2 billion of U.S. retail universal life, variable universal life, universal life with secondary guarantees, and fixed annuity statutory reserves.

The combined value of the transaction is expected to be approximately $3.25 billion with a ceding commission of $2.25 billion and $1 billion of capital that will be released. In addition, MetLife’s Board of Directors has approved a $1 billion increase in the company’s share repurchase authorization. This is incremental to the $3 billion authorization announced earlier in May 2023, and brings MetLife’s total share repurchase authorization outstanding to roughly $4 billion.

The planned reinsurance transaction with Global Atlantic is aligned with MetLife’s disciplined evaluation of risk transfer options within MetLife Holdings, the closed-block businesses of the company’s former U.S. Retail segment. The transaction will accelerate the run-off of MetLife’s legacy business and is the latest tactical milestone in executing across the company’s Next Horizon strategic pillars of focus, simplify and differentiate.

MetLife anticipates that the transaction will positively impact several key financial metrics. These include adding to the company’s adjusted earnings per diluted share and contributing to the company’s 13% to 15% adjusted return on equity target.

“This transaction is another critical step in creating long-term value for our shareholders and for all our stakeholders,” said MetLife President and CEO Michel Khalaf. “It will reduce enterprise risk and enable us to further invest in responsible growth while also returning capital to our shareholders — underscoring our financial strength and our balanced approach to capital management.”


Agreement summary

 

   

MetLife plans to reinsure approximately $19.2 billion U.S. retail life insurance and fixed annuity statutory reserves with Global Atlantic, including $14 billion of U.S. retail life insurance comprised of universal life, variable universal life, and universal life with secondary guarantees, and $5.2 billion of fixed annuities.

 

   

As part of MetLife’s ongoing commitment to its policyholders, the company will continue to be responsible for all customer-related functions.

 

   

MetLife Investment Management secured a mandate to manage a significant amount of the assets under a five-year investment management agreement.

 

   

The reinsurance transaction is structured on a coinsurance and modified coinsurance basis.

 

   

The transaction is expected to close in the second half of 2023. The consummation of the closing under the agreement is subject to the satisfaction or waiver of customary closing conditions specified in the agreement, including the receipt of required regulatory approvals.

Investor Conference Call

On Thursday, May 25, 2023, from 9-9:30 a.m. (ET), MetLife President and CEO Michel Khalaf and MetLife CFO John McCallion will further discuss the agreement with Global Atlantic.

The conference call will be available live via telephone and the internet. To listen via telephone, dial 877-692-8955 (U.S.) or 234-720-6979 (outside the U.S.). The participant access code is 2510803. To listen to the conference call via the internet, click the link to the webcast on the MetLife Investor Relations web page (https://investor.metlife.com). Those who want to listen to the call via telephone or the internet should dial in or go to the website at least 15 minutes prior to the call to register and/or download and install any necessary audio software.

The conference call will be available for replay via telephone and the internet beginning at 2 p.m. (ET) on Thursday, May 25, 2023, until Wednesday, May 31, 2023, at 12 a.m. (ET). To listen to a replay of the conference call via telephone, dial 866-207-1041 (U.S.) or 402-970-0847 (outside the U.S.). The access code for the replay is 6629833. To access the replay of the conference call over the internet, visit the above-mentioned website.

Advisors

Organizations representing MetLife on this transaction include Goldman Sachs & Co. LLC (financial advisor) and Willkie Farr & Gallagher LLP (legal counsel).

Forward Looking and Cautionary Statements

This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.

Many factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors, including those relating to the COVID-19 pandemic, identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:

 

(1)

economic condition difficulties, including risks relating to public health, interest rates, credit spreads, equity, real estate, obligors and counterparties, government default, currency exchange rates, derivatives, climate change and terrorism and security;

 

(2)

global capital and credit market adversity;

 

(3)

credit facility inaccessibility;


(4)

financial strength or credit ratings downgrades;

 

(5)

unavailability, unaffordability, or inadequate reinsurance, including reinsurance risks that arise from reinsurers’ credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;

 

(6)

statutory life insurance reserve financing costs or limited market capacity;

 

(7)

legal, regulatory, and supervisory and enforcement policy changes;

 

(8)

changes in tax rates, tax laws or interpretations;

 

(9)

litigation and regulatory investigations;

 

(10)

London Interbank Offered Rate discontinuation and transition to alternative reference rates;

 

(11)

unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;

 

(12)

MetLife, Inc.’s inability to pay dividends and repurchase common stock;

 

(13)

MetLife, Inc.’s subsidiaries’ inability to pay dividends to MetLife, Inc.;

 

(14)

investment defaults, downgrades, or volatility;

 

(15)

investment sales or lending difficulties;

 

(16)

collateral or derivative-related payments;

 

(17)

investment valuations, allowances, or impairments changes;

 

(18)

claims or other results that differ from our estimates, assumptions, or models;

 

(19)

global political, legal, or operational risks;

 

(20)

business competition;

 

(21)

technological changes;

 

(22)

catastrophes;

 

(23)

climate changes or responses to it;

 

(24)

deficiencies in our closed block;

 

(25)

goodwill or other asset impairment, or deferred income tax asset allowance;

 

(26)

impairment of VOBA, VODA or VOCRA;

 

(27)

product guarantee volatility, costs, and counterparty risks;

 

(28)

risk management failures;

 

(29)

insufficient protection from operational risks;


(30)

failure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;

 

(31)

accounting standards changes;

 

(32)

excessive risk-taking;

 

(33)

marketing and distribution difficulties;

 

(34)

pension and other postretirement benefit assumption changes;

 

(35)

inability to protect our intellectual property or avoid infringement claims;

 

(36)

acquisition, integration, growth, disposition, or reorganization difficulties;

 

(37)

Brighthouse Financial, Inc. separation risks;

 

(38)

MetLife, Inc.’s Board of Directors’ influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and

 

(39)

legal- and corporate governance-related effects on business combinations.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statements if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

Use of Non-GAAP Financial Measures

“Adjusted earnings per diluted share” and “adjusted return on equity” refer to measures that are not presented in accordance with accounting principles generally accepted in the United States (GAAP). “Adjusted earnings per diluted common share” should be read as “adjusted earnings available to common shareholders per diluted common share”, and should not be viewed as a substitute for the most directly comparable financial measure calculated in accordance with GAAP, “net income (loss) available to common shareholders per diluted common share”. “Adjusted return on equity” should be read as “adjusted return on equity, excluding accumulated other comprehensive income other than foreign currency translation adjustments”, and should not be viewed as a substitute for the most directly comparable financial measure calculated in accordance with GAAP, “return on equity”. More information about these measures may be found in our quarterly financial supplement and other documents, which are available on the Investor Relations portion of MetLife’s website, www.metlife.com.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

Contacts

For Media: Brian Blaser (212) 578-2415

For Investors: John Hall (212) 578-7888

EX-99.2 3 d459413dex992.htm EX-99.2 EX-99.2

Exhibit 99.2 MetLife Announces ~$19.2 Billion Risk Transfer Transaction and Increase to Share Repurchase Authorization May 25, 2023


Cautionary Statement on Forward-Looking Statements The forward-looking statements in this presentation, using words such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “grow,” “guidance,” “if,” “intend,” “likely,” “long-term,” “may,” “near-term,” “ongoing,” “outlook,” “plan,” “potential,” “project,” “remain,” “should,” “target,” “to be,” “will,” and “would” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements. 2


Executing on Next Horizon strategy • Entering ~$19.2 billion risk transfer transaction with Global Atlantic Accelerate Run- Reduce Favorable off of Legacy Enterprise Risk Financial Impacts Retail Business 3


1 Transaction overview • Universal life, variable universal life, and universal life with secondary Transaction guarantees statutory reserves totaling $14 billion Scope • Fixed annuity statutory reserves totaling $5.2 billion • Reinsurance on a coinsurance and modified coinsurance basis Transaction • Significant structural protections including investment guidelines and comfort Structure 2 trust overcollateralization • Ceding commission of $2.25 billion • Statutory capital release of ~$1 billion; adds ~60 Combined RBC points Value Received • Share repurchase authorization further increased to $4 billion • Expected to be accretive to adjusted earnings per share Financial • Expected to contribute to adjusted return on equity target of 13-15% 3 Impact • Maintaining free cash flow target ratio of 65-75% of adjusted earnings • Approximately $200 million of foregone adjusted earnings 1 2 Qualified by reference to the more complete description in the MetLife, Inc. Form 8-K dated May 25, 2023, including the news release exhibit thereto. Relative 4 3 to the reinsurer’s coinsurance obligations under the coinsurance agreement. 2-year average excluding total notable items.


Other transaction considerations • Five-year agreement with MetLife Investment Management Investment Management • Covers ~40% of General Account Assets transferred • Continue to be responsible for administration Administration • Continue to provide customer service • Expected to close in second half of 2023 Timing • Subject to regulatory approvals 5


Appendix


Use of Non-GAAP Financial Information Any references in this presentation (except in this Use of Non-GAAP Financial Information) to: Should be read as, respectively: (i) adjusted earnings; (i) adjusted earnings available to common shareholders; (ii) adjusted earnings per share; (ii) Adjusted earnings available to common shareholders per diluted common share; (iii) adjusted return on equity, and (iii) adjusted return on MetLife, Inc’s equity, excluding accumulated other comprehensive income (AOCI) other than foreign currency translation adjustments (FCTA), and (iv) free cash flow (iv) free cash flow of all holding companies In this presentation MetLife presents certain measures of its performance on a basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP: Non-GAAP financial measures: Comparable GAAP financial measures: (i) adjusted earnings available to common shareholders; (i) net income (loss) available to MetLife, Inc.’s common shareholders; adjusted earnings available to common shareholders per diluted common share; net income (loss) available to MetLife, Inc.’s common shareholders per diluted (ii) (ii) common share; (iii) adjusted return on MetLife, Inc’s equity, excluding AOCI other than FCTA, and (iii) Return on equity, and (iv) free cash flow of all holding companies (iv) MetLife, Inc. (parent company only) net cash provided by (used in) operating activities More information about these measures may be found in our quarterly financial supplement and other documents, which are available on the Investor Relations portion of MetLife’s website, www.metlife.com 7